Male-origin microchimerism and endometrial cancer: A prospective case-cohort study.

[1]  A. Tjønneland,et al.  Male origin microchimerism and ovarian cancer. , 2020, International journal of epidemiology.

[2]  Yongxiang Yin,et al.  The levels of the sex hormones are not different between type 1 and type 2 endometrial cancer , 2016, Scientific Reports.

[3]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[4]  A. Vaag,et al.  Microchimerism of male origin in a cohort of Danish girls , 2015, Chimerism.

[5]  Changwei Li,et al.  Parity and endometrial cancer risk: a meta-analysis of epidemiological studies , 2015, Scientific Reports.

[6]  Richard Stevens,et al.  Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. , 2015, The Lancet. Oncology.

[7]  Z. Vernerová,et al.  The occurrence of fetal microchimeric cells in endometrial tissues is a very common phenomenon in benign uterine disorders, and the lower prevalence of fetal microchimerism is associated with better uterine cancer prognoses. , 2014, DNA and cell biology.

[8]  A. Tjønneland,et al.  Opposite effects of microchimerism on breast and colon cancer. , 2012, European journal of cancer.

[9]  S. Scherjon,et al.  Transmaternal cell flow leads to antigen-experienced cord blood. , 2012, Blood.

[10]  K. Helweg-larsen.  The Danish Register of Causes of Death , 2011, Scandinavian journal of public health.

[11]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[12]  Marianne Lundkjær Gjerstorff,et al.  The Danish Cancer Registry , 2011, Scandinavian journal of public health.

[13]  K. Guthrie,et al.  Effect of parity on fetal and maternal microchimerism: interaction of grafts within a host? , 2010, Blood.

[14]  Marielle Martin,et al.  Cells from a vanished twin as a source of microchimerism 40 years later in a male with a scleroderma-like condition. , 2010, Chimerism.

[15]  M. Lipsitch,et al.  Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.

[16]  H. Gammill,et al.  Naturally acquired microchimerism. , 2010, The International journal of developmental biology.

[17]  V. Gadi.  Fetal microchimerism in breast from women with and without breast cancer , 2010, Breast Cancer Research and Treatment.

[18]  K. O'Donoghue.  Fetal microchimerism and maternal health during and after pregnancy , 2008, Obstetric medicine.

[19]  G. Gilmore,et al.  Fetal-maternal microchimerism in normal parous females and parous female cancer patients. , 2008, Experimental hematology.

[20]  L. Vatten,et al.  Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study , 2008, British Journal of Cancer.

[21]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[22]  V. Gadi,et al.  Fetal microchimerism in women with breast cancer. , 2007, Cancer research.

[23]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[24]  A. Tjønneland,et al.  Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark , 2007, Scandinavian journal of public health.

[25]  Ivar Heuch,et al.  Twin births, sex of children and maternal risk of ovarian cancer: a cohort study in Norway , 2007, British Journal of Cancer.

[26]  K. Hemminki,et al.  Endometrial cancer: population attributable risks from reproductive, familial and socioeconomic factors. , 2005, European journal of cancer.

[27]  K. Guthrie,et al.  Male microchimerism in women without sons: quantitative assessment and correlation with pregnancy history. , 2005, The American journal of medicine.

[28]  M. Busch,et al.  High‐level long‐term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury , 2005, Transfusion.

[29]  Million Women Study Collaborators.  Endometrial cancer and hormone-replacement therapy in the Million Women Study , 2005, The Lancet.

[30]  K. Khosrotehrani,et al.  Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse , 2005, Journal of Cell Science.

[31]  Changzhong Chen,et al.  Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. , 2003, Fertility and sterility.

[32]  M. Busch,et al.  Kinetics of fetal cellular and cell‐free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis , 2001, Transfusion.

[33]  D. Purdie,et al.  Epidemiology of endometrial cancer. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[34]  D. Triulzi,et al.  Microchimerism, GVHD, and tolerance in solid organ transplantation , 2001, Transfusion.

[35]  G. Weil,et al.  Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Barlow,et al.  Robust variance estimation for the case-cohort design. , 1994, Biometrics.

[37]  M. Pike,et al.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. , 1988, British Journal of Cancer.

[38]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[39]  R. Greenblatt,et al.  Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. , 1983, American journal of obstetrics and gynecology.